mecamylamine has been researched along with Pervasive Child Development Disorders in 1 studies
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mecamylamine, because of its safety record in children with other disorders, was chosen for this first exploration." | 2.77 | Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders. ( Aman, MG; Anand, R; Arnold, LE; Bates, B; Farmer, C; Hollway, J; Hurt, E; Li, X; Ramadan, Y; Thompson, S; Williams, C, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arnold, LE | 1 |
| Aman, MG | 1 |
| Hollway, J | 1 |
| Hurt, E | 1 |
| Bates, B | 1 |
| Li, X | 1 |
| Farmer, C | 1 |
| Anand, R | 1 |
| Thompson, S | 1 |
| Ramadan, Y | 1 |
| Williams, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neuronal Nicotinic Receptor Modulation in the Treatment of Autism: A Pilot Trial of Mecamylamine[NCT00773812] | Phase 1 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for mecamylamine and Pervasive Child Development Disorders
| Article | Year |
|---|---|
Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders.
Topics: Child; Child Development Disorders, Pervasive; Child, Preschool; Constipation; Dose-Response Relatio | 2012 |